Şahin Duyar Sezgi, Çelik Deniz, Fırat Selma
Deparment of Pulmonology, University of Health Sciences Atatürk Chest Diseases and Thoracic Surgery Education and Research Hospital, Ankara, Turkey.
Sleep Disorders Center, University of Health Sciences Atatürk Chest Diseases and Thoracic Surgery Education and Research Hospital, Ankara, Turkey.
Turk Thorac J. 2021 Nov;22(6):450-458. doi: 10.5152/TurkThoracJ.2021.21058.
The first choice for treatment in severe and moderate obstructive sleep apnea syndrome (OSAS) is positive airway pressurem (PAP) devices. However, despite proper titration, respiratory events may persist, while central respiratory events may increase or emerge for some patients. The primary aim of this study is to compare the clinical, demographic, and polysomnographic features of patients with different titration results.
The patients who underwent automatic PAP (APAP) titration with the nasal mask in our clinic due to moderate or severe OSAS in 2017 were included in the study. The clinical, demographic, and polysomnographic characteristics of patients with successful (good) titration, "unacceptable" APAP titration, and treatment-emergent central apnea syndrome (TECSA), were recorded retrospectively and evaluated comparatively with statistical methods.
Out of 942 titration tests with APAP, 37 patients were diagnosed as TECSA (3.9%), while unacceptable (unsuccessful) titrationresults were seen only in 20 patients (2.1%). For the successful titration group, 44 consecutive patients were recruited. In the TECSA group, the central apnea index and minimum SpO2 were higher during the diagnostic polysomnography (PSG). In the unacceptable titration group, the baseline minimum SpO2 was lower. The lower sleep efficiency, lower stage N3 sleep, and longer rapid eye movement (REM) and sleep latencies were observed in the TECSA group during the titration test. The diagnostic accuracy of PAP device recordings was found to be moderate (kappa value: 0.533).
The baseline polysomnographic features, including higher central apnea index and minimum SpO2, may raise suspicion for titration failures for which a laboratory-based titration can be scheduled.
中重度阻塞性睡眠呼吸暂停综合征(OSAS)的首选治疗方法是气道正压通气(PAP)设备。然而,尽管进行了适当的滴定,但呼吸事件可能仍然存在,而一些患者的中枢性呼吸事件可能会增加或出现。本研究的主要目的是比较不同滴定结果患者的临床、人口统计学和多导睡眠图特征。
纳入2017年因中重度OSAS在我院接受鼻罩自动PAP(APAP)滴定的患者。回顾性记录成功(良好)滴定、“不可接受”的APAP滴定和治疗性中枢性呼吸暂停综合征(TECSA)患者的临床、人口统计学和多导睡眠图特征,并采用统计方法进行比较评估。
在942次APAP滴定测试中,37例患者被诊断为TECSA(3.9%),而仅20例患者(2.1%)出现不可接受(不成功)的滴定结果。对于成功滴定组,连续招募了44例患者。在TECSA组中,诊断性多导睡眠图(PSG)期间的中枢性呼吸暂停指数和最低SpO2较高。在不可接受滴定组中,基线最低SpO2较低。在滴定测试期间,TECSA组观察到睡眠效率较低、N3期睡眠较少、快速眼动(REM)和睡眠潜伏期较长。发现PAP设备记录的诊断准确性中等(kappa值:0.533)。
包括较高的中枢性呼吸暂停指数和最低SpO2在内的基线多导睡眠图特征,可能会增加对滴定失败的怀疑,对此可安排基于实验室的滴定。